Market closedNon-fractional

Caribou Biosciences/CRBU

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Ticker

CRBU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Berkeley, United States

Employees

158

CRBU Metrics

BasicAdvanced
$207M
Market cap
-
P/E ratio
-$1.43
EPS
2.56
Beta
-
Dividend rate
$207M
2.56
10.493
10.255
7.543
7.911
-21.70%
-37.09%
5.542
0.61
0.61
-1.609
127.41%
-19.80%
39.72%
-30.64%

What the Analysts think about CRBU

Analyst Ratings

Majority rating from 9 analysts.
Buy

CRBU Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,716.66% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.4M
-31.43%
Net income
-$41M
19.42%
Profit margin
-1,716.66%
74.15%

CRBU Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.12
-$0.39
-$0.46
-
Expected
-$0.49
-$0.42
-$0.37
-$0.40
-$0.46
Surprise
-3.00%
-71.17%
6.10%
16.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Caribou Biosciences stock?

Caribou Biosciences (CRBU) has a market cap of $207M as of July 23, 2024.

What is the P/E ratio for Caribou Biosciences stock?

The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of July 23, 2024.

Does Caribou Biosciences stock pay dividends?

No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Caribou Biosciences dividend payment date?

Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.

What is the beta indicator for Caribou Biosciences?

Caribou Biosciences (CRBU) has a beta rating of 2.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Caribou Biosciences stock

Buy or sell Caribou Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing